Abstract
Myeloablative conditioning regimens for hematopoietic stem cell transplant (HSCT) are known to affect endocrine function, but little is known regarding reduced intensity conditioning (RIC) regimens. We retrospectively reviewed 114 children and young adults after single RIC HSCT. The analysis was grouped by age (<2 and ⩾2 years) and diagnosis (hemophagocytic lymphohistiocystosis/X-linked lymphoproliferative syndrome (HLH/XLP), other immune disorders, metabolic/genetic disorders). All groups displayed short stature by mean height-adjusted Z-score (HAZ) before (−1.29) and after HSCT (HAZ −1.38, P=0.47). After HSCT, younger children with HLH/XLP grew better (HAZ −3.41 vs −1.65, P=0.006), whereas older subjects had decline in growth (HAZ −0.8 vs −1.01, P=0.06). Those with steroid therapy beyond standard GVHD prophylaxis were shorter than those without (P 0.04). After HSCT, older subjects with HLH/XLP became thinner with a mean body mass index (BMI) Z-score of 1.20 vs 0.64, P=0.02, and similar to metabolic/genetic disorders (BMI-Z= 0.59 vs −0.99, P<0.001). BMI increased among younger children in these same groups. Thyroid function was abnormal in 24% (18/76). 25-OH vitamin D levels were insufficient in 73% (49/65), with low bone mineral density in 8 of 19 evaluable subjects. Despite RIC, children and young adults still have significant late endocrine effects. Further research is required to compare post-transplant endocrine effects after RIC to those after standard chemotherapy protocols.
Similar content being viewed by others
References
Sanders JE . Endocrine complications of high-dose therapy with stem cell transplantation. Pediatr Transplant 2004; 8 (Suppl 5): 39–50.
Baker K, Ness K, Weisdorf D, Francisco L, Sun C, Forman S et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 2010; 24: 2039–2047.
Afify Z, Shaw P, Clavano-Harding A, Cowell C . Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant 2000; 25: 1087–1092.
Dvorak CC, Gracia CR, Sanders JE, Cheng EY, Baker KS, Pulsipher MA et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant 2011; 17: 1725–1738.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant 2015; 21: 1460–1470.
Ding S, Schoenmakers I, Jones K, Koulman A, Prentice A, Volmer D . Quantitative determination of vitamin D metabolites in plasma using UHPLC-MS/MS. Anal Bioanal Chem 2010; 398: 779–789.
Cohen A, Bekassy AN, Gaiero A, Faraci M, Zecca S, Tichelli A et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 (Suppl 2): S43–S48.
Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint M-T, Esperou H et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the working party for late effects—EBMT. Blood 1999; 93: 4109–4115.
Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2014; 99: 2030–2037.
Sanders J, Hawley J, Levy W, Gooley T, Buckner C, Deeg H et al. Pregnancies following high-dose cyclophosphamide with or without high- dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045–3052.
Borgström B, Bolme P . Thyroid function in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 59–64.
Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A et al. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant 1995; 15: 71–76.
Jung MH, Cho KS, Lee JW, Chung NG, Cho B, Suh BK et al. Endocrine complications after hematopoietic stem cell transplantation during childhood and adolescence. J Korean Med Sci 2009; 24: 1071–1077.
Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF et al. Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 2009; 113: 306–308.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930.
Chun RF, Adams JS, Hewison M . Back to the future: a new look at 'old' vitamin D. J Endocrinol 2008; 198: 261–269.
van Etten E, Mathieu C . Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93–101.
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter 2012; 34: 109–133.
Brennan BM, Shalet SM . Endocrine late effects after bone marrow transplant. Br J Haematol 2002; 118: 58–66.
Ranke MB, Schwarze CP, Dopfer R, Klingebiel T, Scheel-Walter HG, Lang P et al. Late effects after stem cell transplantation (SCT) in children—growth and hormones. Bone Marrow Transplant 2005; 35 (Suppl 1): S77–S81.
Acknowledgements
We thank Cyrus Yang and Ryan Judd for their assistance with data collection.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Myers, K., Howell, J., Wallace, G. et al. Poor growth, thyroid dysfunction and vitamin D deficiency remain prevalent despite reduced intensity chemotherapy for hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplant 51, 980–984 (2016). https://doi.org/10.1038/bmt.2016.39
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.39
- Springer Nature Limited
This article is cited by
-
Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
Journal of Clinical Immunology (2023)
-
Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases
Bone Marrow Transplantation (2022)
-
High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS)
International Journal of Hematology (2019)